News
Acadia Pharma To Present Data From Its Pimavanserin Phase II Schizophrenia Co-therapy Trial
Tuesday morning, biopharmaceutical company Acadia Pharmaceuticals, Inc. said that it would present data from its pimavanserin Phase II schizophrenia co-therapy trial on February 5, 2008.
The company said that the Phase II trial demonstrates several advantages of co-therapy with pimavanserin, which include an enhanced efficacy, a faster onset of antipsychotic action, and an improved side effect profile, including less weight gain.
The company also would present new data from this study showing that patients in the co-therapy arm combining pimavanserin with risperidone had significantly less increase from baseline in serum glucose levels after treatment compared to patients in the risperidone plus placebo arm.
Taken together, the reductions in weight gain and glucose increase seen after effective antipsychotic treatment with pimavanserin and a sub-maximal dose of risperidone suggest that this co-therapy approach has the potential to reduce the metabolic problems commonly associated with atypical antipsychotics.
Schizophrenia is a chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction, and behavior. Nearly 1% of the population develops schizophrenia during their lifetime and more than two million people in the United States suffer from this disease.
ACAD's stock is currently trading at $12.51, down 87 cents or 6.50% from its previous closing of $13.38.